Takeda Strikes Possible Deal, Halts Nev. Actos Cancer Trial

Law360, Los Angeles (October 8, 2015, 8:02 PM EDT) -- Takeda Pharmaceutical Co. Ltd. said Thursday it has reached a tentative settlement mid-trial with two Nevada plaintiffs alleging the company's diabetes drug Actos caused cancer, halting the jury trial after more than a month of arguments and testimony.

The settlement comes as more than 97 percent of eligible claimants have opted into Takeda's $2.4 billion settlement program, the drugmaker told Law360 on Thursday. The deal would resolve most of the outstanding lawsuits over the drug, including nine that have been tried and are currently in appeals.

However, a Takeda spokeswoman said in a written statement that the settlement is not an...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS